What Civatech Oncology does

CivaTech Oncology Inc. is a privately held medical device company founded in 2006 and headquartered in Durham, North Carolina (Research Triangle Park). The company develops and commercializes polymer-encapsulated low-dose-rate (LDR) brachytherapy devices that use palladium-103 (Pd-103) as the radioactive source. Its core products are CivaString, a linear polymer-encapsulated brachytherapy source first FDA-cleared in 2013 for treating localized solid tumors (initially prostate cancer); CivaSheet, a bioabsorbable unidirectional planar brachytherapy device FDA-cleared in 2014; and CivaDerm, a temporary surface/intraoperative radiation product FDA-cleared in 2022 for skin cancer and other lesions. The company's proprietary polymer encapsulation replaces traditional metal seed encapsulation, eliminating long-term metal toxicities and source migration while enabling directional (unidirectional) radiation emission and homogeneous dose distribution.

CivaTech operates as a niche radiation oncology device manufacturer with ISO 13485-certified and FDA 21 CFR Part 820-compliant clean room manufacturing, plus two NRC Agreement State licenses (North Carolina) authorizing research, manufacture, and distribution of radioactive sealed sources. The company sells directly to radiation oncologists, medical physicists, and hospital radiation oncology departments, with devices customized per patient prescription. Commercial deployment is supported by peer-reviewed publications, abstracts, professional education resources, and NIH/NCI-sponsored multi-institutional clinical trials at sites including Memorial Sloan Kettering, VCU, Fox Chase, Honor Health, Rush Medical Center, Advocate Healthcare, and LSU, with indications spanning prostate, pancreas, lung, colorectal, head and neck, sarcoma, GYN, and skin cancers.

The company's revenue model is hardware sales of customized medical devices to healthcare facilities, with pricing not publicly disclosed. CivaTech has funded operations primarily through small grants and equity rounds totaling approximately $13 million across 13 disclosed rounds from 2009-2023, including a $4 million NIH/NCI grant in August 2023 to commercialize CivaSheet for pancreatic cancer. The leadership team is led by founder and Executive Chairman/CEO Suzanne Troxler Babcock, with a Chief Science Officer, Chief Medical Officer, VP of Clinical Programs, and National Sales Manager. There are no disclosed venture capital or institutional growth equity rounds, no M&A activity, and the company remains privately held with 11-50 employees.

Name

Civatech Oncology

Legal name

CivaTech Oncology Inc.

Website

https://civatechoncology.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

CivaTech Oncology is a privately held medical device company developing polymer-encapsulated low-dose-rate brachytherapy devices (CivaString, CivaSheet, CivaDerm) using Pd-103 for treating solid tumor cancers, selling directly to hospital radiation oncology departments.

Ownership category

akta.pro rank

Product category

Radiation Therapy Medical Devices

NAICS

Irradiation Apparatus Manufacturing (334517), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industries

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD), Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH), Medical Oncology (HLAKAFAB)

Keywords

• Brachytherapy devices
• Radiation oncology
• Polymer encapsulated sources
• Cancer treatment devices
• LDR brachytherapy

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Sales: CivaTech Oncology generates revenue through the sale of its proprietary brachytherapy devices (CivaSheet, CivaString, CivaDerm) to hospitals and radiation oncology departments. Products are customized for individual patients based on prescription requirements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CivaTech Oncology designs, manufactures, and sells polymer-encapsulated low-dose-rate (LDR) brachytherapy medical devices used by radiation oncologists to deliver targeted, localized radiation therapy to solid tumors. Its portfolio includes CivaString (linear source), CivaSheet (unidirectional bioabsorbable planar source), and CivaDerm (temporary surface/intraoperative radiation), each FDA-cleared for treating cancers including prostate, pancreas, sarcoma, head and neck, lung, colorectal, breast, and brain tumors.

Product overview

CivaTech Oncology develops and commercializes a portfolio of innovative polymer-based low-dose rate (LDR) brachytherapy devices for cancer treatment. The product line consists of three FDA-cleared devices: CivaString (linear polymer-encapsulated brachytherapy source launched 2013), CivaSheet (bioabsorbable unidirectional planar source launched 2014), and CivaDerm (temporary surface/intraoperative radiation product launched 2022). These devices integrate into clinical workflows for treating various solid tumor cancers including prostate, pancreas, colorectal, head and neck, lung, sarcoma, and skin cancer.

Differentiator

Problem solved

Functional benefit

Brands

• CivaSheet: FDA cleared, unidirectional, planar brachytherapy source. It is flexible, bioabsorbable and features proprietary polymer encapsulated source technology for targeted radiation therapy.
• CivaString
• CivaDerm

Products and services

• CivaSheet® FDA-cleared, unidirectional, planar, flexible, bioabsorbable low-dose-rate (LDR) brachytherapy source with proprietary polymer-encapsulated palladium-103 source technology. The only bioabsorbable and directional radiation therapy device approved by the FDA, designed to deliver targeted radiation while shielding healthy tissue for treating solid tumor cancers.
• CivaString® Unique linear, polymer-encapsulated low-dose-rate (LDR) brachytherapy source containing palladium-103 (Pd-103) along the full length of the device. Low-Z polymer construction creates homogeneous dose distribution for treating localized, solid tumors including prostate cancer.
• CivaDerm™ FDA-cleared temporary radiation therapy product designed for intraoperative or surface radiation to treat skin cancer and other lesions. Used in bandage format to treat non-melanoma skin cancers, keloids, and other lesions in approximately 5 days.

Quantifiable outcome

• 99.9% coverage of prostate achieved using 12 needles with CivaString
• +5 more outcomes

Named customers9 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core.

• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerDr. Abe Wu is Principal Investigator for the multi-institutional NIH/NCI sponsored clinical study to treat lung cancer with CivaSheet. This is a key clinical research partnership.
• Virginia Commonwealth UniversitycoreStrategic or Co-development PartnerMulti-center NIH sponsored study for pancreatic cancer treatment with CivaSheet is underway. VCU in Richmond, VA is currently recruiting patients for the study.
• Fox Chase Cancer CentercoreStrategic or Co-development PartnerMulti-center NIH sponsored study for pancreatic cancer treatment with CivaSheet. Fox Chase Cancer Center in Philadelphia, PA is currently recruiting patients.
• Honor HealthcoreStrategic or Co-development PartnerMulti-center NIH sponsored study for pancreatic cancer treatment with CivaSheet. Honor Health in Phoenix, Arizona is currently recruiting patients.
• Rush Medical CentercoreStrategic or Co-development PartnerMulti-center NIH sponsored study for pancreatic cancer treatment with CivaSheet. Rush Medical Center in Chicago, IL is currently recruiting patients.
• Advocate HealthcarecoreStrategic or Co-development PartnerMulti-center NIH sponsored study for pancreatic cancer treatment with CivaSheet. Advocate Healthcare in Chicago, IL is currently recruiting patients.
• Louisiana State University (LSU)coreStrategic or Co-development PartnerMulti-center NIH sponsored study for pancreatic cancer treatment with CivaSheet. LSU in New Orleans, LA is currently recruiting patients.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Elekta: Global leader in radiation therapy and radiosurgery, including a broad brachytherapy afterloader and applicator portfolio. Comparable because Elekta competes with CivaTech in the same radiation-oncology buyer base and LDR/HDR brachytherapy market, but at vastly larger scale and across many more modalities.
• Varian (a Siemens Healthineers company): Dominant radiation oncology incumbent with linear accelerators, treatment planning software, and brachytherapy solutions. Comparable as a same-buyer radiation-oncology incumbent whose installed base and clinical workflow integrations compete with CivaTech's polymer brachytherapy devices for hospital capital and operating budgets.
• BD (Bard Medical, brachytherapy division): Through its Bard acquisition, BD has historically sold brachytherapy seeds and accessories, making it a broad incumbent competitor in the LDR seed market that CivaString directly addresses — particularly in prostate cancer.
• Mevion Medical Systems: Compact proton therapy system vendor serving the same radiation-oncology buyer base as CivaTech. Comparable as an adjacent radiation-therapy equipment vendor competing for the same hospital capital budgets, though in a different modality (protons vs. LDR brachytherapy).

Direct peers

• Eckert & Ziegler BEBIG: European-based brachytherapy specialist offering LDR seeds (e.g., I-125, Pd-103) and HDR afterloaders. A direct competitor to CivaString and CivaSheet in the LDR brachytherapy seed/source category, serving the same radiation oncologists and prostate-cancer workflows.
• IsoRay Medical (Viewpoint Molecular Targeting / Isoray): U.S.-based brachytherapy seed company specializing in Cesium-131 and Pd-103 LDR seeds for prostate and other cancers. Directly comparable as a small, focused LDR brachytherapy seed/device company competing for the same radiation-oncology customer accounts.
• Theragenics / Perspective Therapeutics: Brachytherapy seed and device manufacturer (AgX100, palladium and iodine seeds) serving prostate and other solid-tumor indications. A focused direct peer to CivaTech in polymer/metal-encapsulated LDR brachytherapy sources.
• Best Medical International: Specialty manufacturer of brachytherapy seeds (I-125, Pd-103), strands, and accessories used in prostate and other solid-tumor treatments. Comparable as a smaller direct competitor in the same LDR brachytherapy seed market targeted by CivaString.
• IsoAid: U.S. brachytherapy seed manufacturer offering palladium-103 and iodine-125 LDR seeds. Directly comparable as a small specialty player competing head-to-head with CivaString in prostate brachytherapy.

Emerging players

• GT Medical Technologies: Emerging radiation-therapy company (GammaTile) delivering localized radiation therapy for brain tumors and other solid tumors. Comparable as a smaller, indication-focused radiation-therapy device company pursuing the same narrative of targeted, tissue-sparing brachytherapy-style treatment that CivaTech is building with CivaSheet.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CivaTechOnc
• LinkedInlinkedin.com/company/civatech-oncology-inc-

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds13 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Civatech Oncology